Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label immunogenicity and safety study of Gardasil 9 in Chinese males aged 9-19 years
CTR20220441Phase 3Active
- Sponsor
- Merck & Co.
- Start
- May 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, anogenital warts, penile intraepithelial neoplasia (PeIN), anal intraepithelial neoplasia (AIN), penile cancer, sponsored by Merck & Co.. Started May 2022; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionanogenital wartspenile intraepithelial neoplasia (PeIN)anal intraepithelial neoplasia (AIN)penile cancer
Beyond the preview
Go deeper on CTR20220441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220441.